Investors Alert: Class Action Launched Against REGENXBIO, Inc. Over Alleged Company Misconduct

RGNX Stockholder Alert: Robbins LLP and the Class Action

Overview of the Situation

Robbins LLP, a leading firm in shareholder rights litigation, is drawing attention to a class action lawsuit against REGENXBIO, Inc. (NASDAQ: RGNX). This lawsuit was initiated on behalf of investors who acquired REGENXBIO securities between February 9, 2022, and January 27, 2026. Investors in the biotechnology firm, known for its gene therapies, are now faced with significant concerns regarding misleading information related to the company's drug candidate, RGX-111.

Allegations Against REGENXBIO

The legal complaint filed by Robbins LLP outlines serious allegations that REGENXBIO executives misrepresented the safety and viability of their clinical-stage product RGX-111. This revolutionary drug was being pursued for the treatment of Mucopolysaccharidosis Type I (MPS I) using what the company touted as a proprietary NAV AAVP vector. Since its initial announcement in 2018, REGENXBIO had consistently claimed that RGX-111 was encountering favorable outcomes during clinical trials, emphasizing “positive interim safety, tolerability, and biomarker data.”

However, it has come to light that the company was allegedly aware of severe safety concerns tied to the RGX-111 trials, particularly the potential for serious adverse health conditions, including central nervous system tumors. Despite this knowledge, REGENXBIO continued to promote the drug’s safety and positive progress — an action that has now resulted in legal action, as shareholders feel misled about the risks associated with their investments.

Development of the Class Action Lawsuit

The situation escalated significantly when, on January 28, 2026, REGENXBIO announced that the FDA had issued a clinical hold on RGX-111 following preliminary findings of a participant developing a neoplasm during the study. This was not only a blow to the reputation of the drug but also to the overall trust in the company. The announcement caused REGENXBIO’s stock to plummet by 17.8% in a single day, highlighting the negative impact of the misleading information on investor confidence.

The lawsuit seeks to bring accountability to REGENXBIO’s executives and potentially secure compensation for those who bought its stocks under the false impressions created by the company’s public statements.

Next Steps for Investors

Investors who bought shares of REGENXBIO during the specified period may be eligible to participate in the class action lawsuit. To become an active participant, stockholders must submit their documentation to the court by April 14, 2026. While individuals have the option to opt out of participating in order to remain class members, engaging in the class action provides a platform for collectively addressing the damages resulting from the alleged misleading information.

It’s crucial for affected investors to understand their rights and the mechanisms through which they can seek redress. Robbins LLP operates on a contingency fee basis, meaning that those involved in this class action will not be liable for any fees unless a recovery occurs. This provides reassurance to investors who may be hesitant to pursue action due to potential costs.

About Robbins LLP

As a powerhouse in the realm of shareholder litigation, Robbins LLP has been operating since 2002, focusing on helping shareholders recover losses and pressuring corporate executives to uphold responsibility. Their commitment to justice is apparent in this ongoing case against REGENXBIO and serves as an essential reminder for investors about the importance of accountability in corporate governance.

For up-to-date information, investors can sign up for alerts related to this class action and other potential litigation involving corporate misdeeds, ensuring they remain aware of their rights as shareholders in the ever-evolving biotechnology landscape.